Form 4: Enliven Therapeutics CFO Benjamin Hohl Executes Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On February 5, 2025, Benjamin Hohl, the CFO of Enliven Therapeutics, exercised options to purchase 1,000 shares of common stock at a price of $2.48 per share.
- Simultaneously, Hohl sold 1,000 shares of common stock at a weighted average price of $22.5244, with individual sales prices ranging from $22.50 to $22.54.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
- Following these transactions, Hohl directly owns 13,000 shares of common stock and holds options for 146,056 shares.
- The options vest over time, with the initial vesting occurring on August 2, 2022, and the remaining shares vesting in equal monthly installments over 36 months.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports routine transactions under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. The use of a 10b5-1 plan is a common practice to allow insiders to sell shares without being accused of trading on non-public information.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their insiders.
- The use of Rule 10b5-1 trading plans is a common and accepted method for corporate insiders to manage their stock holdings while avoiding potential insider trading accusations.
- Comparable companies such as Relay Therapeutics, Black Diamond Therapeutics, and Blueprint Medicines also have executives who utilize 10b5-1 plans for trading their company stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the small volume of shares sold.
- The transactions do not appear to have a significant impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| June 26, 2023 | Date the Reporting Person adopted the Rule 10b5-1 trading plan |
| August 2, 2022 | Initial vesting date for the stock options |
| February 5, 2025 | Date of the option exercise and share sale |
| August 2, 2031 | Expiration date of the stock options |
| February 7, 2025 | Date of the Form 4 signature |
Keywords
Form 4, Enliven Therapeutics, Benjamin Hohl, Stock Options, Share Sale, Rule 10b5-1, ELVN, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.